ISU Abxis Co. Ltd (086890) - Total Liabilities

Latest as of September 2025: ₩45.29 Billion KRW ≈ $30.69 Million USD

Based on the latest financial reports, ISU Abxis Co. Ltd (086890) has total liabilities worth ₩45.29 Billion KRW (≈ $30.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 086890 cash flow conversion to assess how effectively this company generates cash.

ISU Abxis Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how ISU Abxis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check ISU Abxis Co. Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

ISU Abxis Co. Ltd Competitors by Total Liabilities

The table below lists competitors of ISU Abxis Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
AGFA Gevaert NV
BR:AGFB
Belgium €1.00 Billion
Inpro SA
WAR:INP
Poland zł381.27 Million
Ilshinstone
KO:007110
Korea ₩34.89 Billion
Seker Gayrimenkul Yatirim Ortakligi A.S.
IS:SEGYO
Turkey TL1.08 Billion
Cintac
SN:CINTAC
Chile CL$459.47 Million
Transart Graphics Co Ltd
TW:8481
Taiwan NT$193.97 Million
Nuveen California Select Tax Free Income Closed Fund
NYSE:NXC
USA $795.79K
Alcadon Group AB
ST:ALCA
Sweden Skr737.80 Million

Liability Composition Analysis (2014–2024)

This chart breaks down ISU Abxis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ISU Abxis Co. Ltd (086890) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.38 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ISU Abxis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ISU Abxis Co. Ltd (2014–2024)

The table below shows the annual total liabilities of ISU Abxis Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩59.37 Billion
≈ $40.23 Million
-54.17%
2023-12-31 ₩129.55 Billion
≈ $87.79 Million
+77.81%
2022-12-31 ₩72.86 Billion
≈ $49.38 Million
-7.94%
2021-12-31 ₩79.14 Billion
≈ $53.63 Million
+102.03%
2020-12-31 ₩39.17 Billion
≈ $26.55 Million
+4.24%
2019-12-31 ₩37.58 Billion
≈ $25.47 Million
+271.87%
2018-12-31 ₩10.11 Billion
≈ $6.85 Million
-35.69%
2017-12-31 ₩15.71 Billion
≈ $10.65 Million
+10.23%
2016-12-31 ₩14.26 Billion
≈ $9.66 Million
-39.11%
2015-12-31 ₩23.41 Billion
≈ $15.87 Million
-25.87%
2014-12-31 ₩31.59 Billion
≈ $21.41 Million
--

About ISU Abxis Co. Ltd

KQ:086890 Korea Pharmaceuticals
Market Cap
$85.89 Million
₩126.74 Billion KRW
Market Cap Rank
#19763 Global
#1119 in Korea
Share Price
₩4760.00
Change (1 day)
-1.86%
52-Week Range
₩4410.00 - ₩6240.00
All Time High
₩22450.00
About

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more